Introduction
============

Cluster of differentiation 168 (CD168), also known as receptor for hyaluronan mediated motility, is a hyaluronan (HA)-binding protein, which is expressed in various tumors, including breast, gastric, prostate and colorectal cancer (CRC) ([@b1-ol-0-0-4974]--[@b4-ol-0-0-4974]). CD168 was originally identified as a HA-dependent motility cell surface receptor, which transforms fibroblasts when overexpressed ([@b5-ol-0-0-4974]). CD168 has been identified in cytoplasmic and nuclear compartments where it interacts with interphase microtubules and centrosomes and regulates the tumor suppressor gene, breast cancer 1 ([@b6-ol-0-0-4974]). In addition, a previous study demonstrated that CD168 activates downstream signaling, such as Rho GTPase kinase cascades, and increases cellular motility ([@b7-ol-0-0-4974]). Notably, CD168 is often upregulated in multiple cancers and has subsequently been linked to cancer progression ([@b8-ol-0-0-4974],[@b9-ol-0-0-4974]). Clinically, the accumulation of HA within the cancer or peritumor stroma has been identified as a marker of poor prognosis in breast cancer patients ([@b10-ol-0-0-4974]). In addition, Ishigami *et al* ([@b11-ol-0-0-4974]) revealed that the expression of CD168 was significantly associated with biological aggressiveness in gastric cancer ([@b11-ol-0-0-4974]). Therefore, it is important to validate the function of CD168 in clinical samples. This presents a critical step toward the development of effective therapeutic intervention. Therefore, the present study investigated the clinical features of CD168 expression and analyzed the association between CD168 expression and the clinical outcome of CRC patients following surgical resection.

Materials and methods
=====================

### Patients and specimens

A total of 78 consecutive patients with primary colorectal adenocarcinomas (stage I--IV) who underwent curative surgical resection at The Second Affiliated Hospital (Hangzhou, China) between January 2006 and November 2012, with data available for study in the archives of the Department of Pathology, were included in the study. All patients were followed-up for ≥5 years or until mortality. All histopathological information was systematically re-reviewed from the corresponding hematoxylin and eosin stained tissues, including tumor-node-metastasis (TNM) classification, tumor grade and histological subtype, according to the American Joint Committee on Cancer staging system ([@b12-ol-0-0-4974]). Clinical information was obtained from patient records and included age, gender, tumor location and survival time. The pathological and clinical information of the patients is summarized in [Table I](#tI-ol-0-0-4974){ref-type="table"}. The present study was approved by the Research Ethics Board at Zhejiang University (Hangzhou, Zhejiang, China).

### Tissue microarray (TMA)

A TMA was assembled using tissues obtained from 78 primary CRC patients according to the following procedure. Briefly, the TMA was assembled using a needle to obtain a donor core from morphologically representative areas of donor tissue blocks and mounted into the recipient paraffin block using a custom-made precision instrument (Beecher Instruments, Inc., Sun Prairie, WI, USA). TMA sections (0.6-mm thick) were cut and placed onto slides using standard techniques ([@b13-ol-0-0-4974]).

### Immunohistochemical staining

The expression of CD168 in CRC tissues was evaluated according to the following procedure. Antigen retrieval was performed in phosphate-buffered saline (PBS) with 3% citrate buffer at 120°C for 10 min. Slides were then cooled at room temperature (RT) for 10 min, rinsed in PBS buffer solution and placed in the Autostainer Link 48 (Dako, Glostrup, Denmark) for staining. Rabbit monoclonal CD168 antibody (catalog no. EPR4055; Epitomics, Burlingame, CA, USA), diluted to 1:100 with PBS, was applied and incubation was performed for 30 min at RT. Tumor tissues were then visualized using the avidin biotinylated peroxidase method ([@b14-ol-0-0-4974]), in accordance with the manufacturer\'s instructions (Jinqiao Biological Technology Co., Beijing, China). Sections were then treated with streptavidin-peroxidase complex. Cases previously known to be positive were used as positive controls (MCF-7 cell lysate paraffin-embedded breast carcinoma tissues; MCF-7 cells were purchased from the Cell Bank of the Chinese Academy of Medical Science, Beijing, China). Cell-infiltrating cancer in stained sections was used as a negative control.

### Evaluation of CD168 protein expression

CD168 expression in CRC was analyzed, as described previously ([@b15-ol-0-0-4974]). Briefly, the intensity of immunohistochemical staining was evaluated by two independent pathologists, who were blinded to the clinical data and disease outcome. In cases of discrepant assessments, the sections were evaluated using a double-headed microscope and staining was discussed until an agreement was reached. CD168 staining was classified into three categories: 0, no staining; 1, weak membranous and cytoplasmic expression in \>10% of cancer cells; 2, weak to moderate expression in \>10% of the cancer cells; and 3, strong expression in \>10% of the cancer cells. The association between clinicopathological factors and CD168 expression was then investigated.

### Statistical analysis

Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Clinicopathological factors were evaluated using the χ^2^ test and Fisher\'s exact test was used to assess the significance between categorical variables. Survival curves of positive or negative CD168 overexpression groups were generated using the Kaplan-Meier method and statistical significance was determined by log-rank test. Cox regression analysis was used for multivariate analysis of independent prognostic factors for survival. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### CD168 expression in CRC tissues

CD168 expression was identified on the cell membrane and in the cytoplasm ([Fig. 1](#f1-ol-0-0-4974){ref-type="fig"}). Of the 78 patients, 72 (92.3%) cases exhibited positive membrane or cytoplasmic CD168 expression, whereas 6 (7.7%) cases exhibited negative CD168 expression. Subsequently, the patients were divided into two groups according to CD168 expression: i) CD168 overexpression negative group (patients exhibiting no, weak and moderate staining of tumor cells in the entire cancer area; and ii) CD168 overexpression positive group (staining intensity \>2). Normal colonic epithelium exhibited no expression of CD168.

### Association between CD168 overexpression and clinicopathological features

Clinicopathological analysis revealed that CD168 overexpression was more common in female patients than male patients (P=0.04) ([Table II](#tII-ol-0-0-4974){ref-type="table"}). However, no statistically significant associations were identified between CD168 overexpression and other clinicopathological features, including age, tumor size, tumor location, histology and TNM classification.

### Association between CD168 overexpression and overall survival of CRC patients

The 5-year survival rates of the CD168 overexpression negative and positive groups were 83.3 and 40%, respectively. The association between CD168 overexpression and overall survival in colorectal adenocarcinoma patients was analyzed using Kaplan-Meier analysis. Patients of the CD168 overexpression positive group exhibited significantly worse survival than that of CD168 overexpression negative group (P=0.002) ([Fig. 2](#f2-ol-0-0-4974){ref-type="fig"}). Multivariate Cox regression analysis revealed that CD168 overexpression was a negative prognostic factor for the CD168 overexpression positive group when compared with that of the CD168 overexpression negative group (P\<0.05).

These data indicate that CD168 expression is an independent adverse survival factor in CRC.

Discussion
==========

A number of studies have indicated that CD168 expression is significantly associated with high metastatic potential or cancer progression in multiple myeloma, gastric, breast and pancreatic cancers ([@b11-ol-0-0-4974],[@b16-ol-0-0-4974]--[@b18-ol-0-0-4974]). In the present study, the results indicate that overexpression of the CD168 protein leads to reduced overall survival and is an independent adverse survival factor in CRC. In accordance with the results of the present study, Zlobec *et al* ([@b19-ol-0-0-4974]) reported that the combined immunohistochemical profile of CD168/tumor infiltrating lymphocytes could identify patients with an adverse prognosis. However, the study investigated the clinical impact of CD168 expression in rectal cancer, and did not include CRC. Therefore, further investigation is required to elucidate the association between CD168 expression and clinical factors in CRC.

CD168 is an 85 kDa multifunctional protein that is often upregulated in advanced malignancies. It is involved in cell motility and signaling, as well as oncogenic events. CD168 exists in several variant forms and may be expressed at the cell surface and intracellularly, where it exhibits different functions ([@b20-ol-0-0-4974],[@b21-ol-0-0-4974]). When expressed at the cell surface, CD168 acts as a receptor for HA, which has been implicated in cancer cell invasiveness ([@b22-ol-0-0-4974]). A previous study demonstrated that CD168 binds to HA and modulates microtubule-associated protein interactions with actin ([@b23-ol-0-0-4974]). Yamada *et al* ([@b24-ol-0-0-4974]) reported that increased mRNA expression of CD168 at various stages of CRC was associated with cancer progression. Furthermore, Zlobec *et al* ([@b25-ol-0-0-4974]) suggested that CD168 expression is an important contributor to CRC cell migration and dispersal, regardless of whether tumors were lymph node-positive or negative. These data are consistent with the results of the present study.

Immunohistochemical analysis in the present study indicates that CD168 overexpression is not associated with common clinical parameters of CRC, such as tumor location, tumor differentiation or TNM stage. However, high CD168 expression was an important prognostic factor in patients with CRC. Considering the function of CD168 as a receptor and its involvement in the Ras/mitogen-activated protein kinase signaling pathway ([@b14-ol-0-0-4974],[@b26-ol-0-0-4974]), CD168 may present a potential candidate for therapeutic intervention. Therefore, further studies of CD168 and its potential as a marker for CRC prognosis in the clinic are required.
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![Representative images of (A) negative and (B) intense positive CD168 expression in tissue microarrays of colorectal cancer. ×40 magnification.](ol-12-04-2555-g00){#f1-ol-0-0-4974}

![Kaplan-Meier survival analysis of colorectal cancer (CRC) patients negative or positive for CD168 overexpression. CD168 overexpression was associated with shorter overall survival times. Analysis of (A) all patients, (B) patients with stage I+II CRC and (C) patients with stage III+IV CRC.](ol-12-04-2555-g01){#f2-ol-0-0-4974}

###### 

Clinicopathological data of the 78 colorectal cancer patients included in the present study.

  Clinicopathological parameter                            Patient, n (%)
  -------------------------------------------------------- ----------------
  Gender                                                   
    Male                                                     52 (66.7)
    Female                                                   26 (33.3)
  Age, years                                               
    \<65                                                     41 (52.6)
    ≥65                                                      37 (47.4)
  Tumor location                                           
    Colon                                                    38 (48.7)
    Rectum                                                   40 (51.3)
  Histological differentiation                             
    Well-differentiated                                      26 (33.3)
    Moderately-differentiated                                36 (46.2)
    Poorly-differentiated                                    16 (20.5)
  Tumor stage                                              
    T1                                                       1 (1.3)
    T2                                                       7 (9.0)
    T3                                                       30 (38.5)
    T4                                                       40 (51.3)
  Lymph node involvement                                   
    N0                                                       42 (53.8)
    N1                                                       24 (30.8)
    N2                                                       12 (15.4)
  Metastasis                                               
    M0                                                       73 (93.6)
    M1                                                       5 (6.4)
  TNM stage^[a](#tfn1-ol-0-0-4974){ref-type="table-fn"}^   
    I                                                        5 (6.4)
    II                                                       37 (47.4)
    III                                                      31 (39.7)
    IV                                                       5 (6.4)

American Joint Committee on Cancer staging system. TNM, tumor-node-metastasis.

###### 

Correlation between CD168 OE and clinicopathological parameters of 78 colorectal patients.

                                                           CD168 OE         
  -------------------------------------------------------- ---------- ----- ---------------------------------------------------
  Gender                                                                    0.04
    Male                                                   46           6   
    Female                                                 18           8   
  Age, years                                                                0.62
    \<65                                                   34           7   
    ≥65                                                    29           8   
  Tumor location                                                            0.20
    Colon                                                  29           9   
    Rectum                                                 35           5   
  Histological differentiation                                              0.41^[a](#tfn2-ol-0-0-4974){ref-type="table-fn"}^
    Well-differentiated                                    25           1   
    Moderately-differentiated                              27           9   
    Poorly-differentiated                                  12           4   
  Tumor stage                                                               0.67^[b](#tfn3-ol-0-0-4974){ref-type="table-fn"}^
    T1                                                       1          0   
    T2                                                       6          1   
    T3                                                     24           6   
    T4                                                     33           7   
  Lymph node involvement                                                    0.78^[c](#tfn4-ol-0-0-4974){ref-type="table-fn"}^
    N0                                                     34           8   
    N1                                                     22           2   
    N2                                                       8          4   
  Metastasis                                                                0.23
    M0                                                     60         13    
    M1                                                       4          1   
  TNM stage^[d](#tfn5-ol-0-0-4974){ref-type="table-fn"}^                    0.78^[e](#tfn6-ol-0-0-4974){ref-type="table-fn"}^
    I                                                        4          1   
    II                                                     30           7   
    III                                                    26           5   
    IV                                                       4          1   

Well- and moderately-differentiated vs. poorly-differentiated.

T1+T2 vs. T3+T4.

N0 vs. N1+N2.

^a^American Joint Committee on Cancer staging system.

I+II vs. III+IV. (−), negative overexpression; (+), positive overexpression; CD168, cluster of differentiation 168; OE, overexpression; TNM, tumor-node-metastasis.
